Earnings Summary

Oncternal Therapeutics Inc’s revenue jumped 73.68% since last year same period to $0.3Mn in the Q4 2023. On a quarterly growth basis, Oncternal Therapeutics Inc has generated 65.92% jump in its revenue since last 3-months.

Oncternal Therapeutics Inc’s net profit jumped 15.81% since last year same period to $-9.16Mn in the Q4 2023. On a quarterly growth basis, Oncternal Therapeutics Inc has generated 7.08% jump in its net profits since last 3-months.

Oncternal Therapeutics Inc’s net profit margin jumped 51.53% since last year same period to -3085.52% in the Q4 2023. On a quarterly growth basis, Oncternal Therapeutics Inc has generated 44% jump in its net profit margins since last 3-months.

Oncternal Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -2.87 - a 6.51% jump from last quarter’s estimates.

Oncternal Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -2.87.

Oncternal Therapeutics Inc’s earning per share (EPS) fell -1455% since last year same period to -3.11 in the Q4 2023. This indicates that the Oncternal Therapeutics Inc has generated -1455% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Oncternal Therapeutics Inc’s return on assets (ROA) stands at -0.49.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Oncternal Therapeutics Inc’s return on equity (ROE) stands at -0.87.